Navigation Links
Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2007
Date:11/6/2007

food-related product designed to promote healthy lifestyle choices for

global consumers. Under the agreement between Verenium and Cargill,

Verenium is applying its enzyme discovery and optimization technologies

to develop several new custom enzymes for Cargill which are being

utilized as part of Cargill's innovative, multi-step enzymatic process

to develop a new food-related product.

Corporate Strategy

The Company continues to focus on several key initiatives and opportunities critical to its successful future development in the alternative energy marketplace:

-- Verenium believes strategic partnerships and alliances will be critical

ingredients to catalyze growth and success in this multi-billion dollar

global market. As such, the Company maintains active and on-going

dialogues with a broad cross-section of potential strategic partners

that could serve to accelerate its commercial development plans. The

Company's goal is to identify one or a series of partners with

complementary business offering(s), financial resources, and a shared

vision for cellulosic ethanol development to accelerate its commercial

plans, and expects to advance these discussions over the coming year.

-- From a public policy standpoint, Verenium continues to be committed to

maximizing opportunities at both the federal and state levels in the

form of grants and other funding. Further, the Company is also closely

following both energy and agriculture legislation currently being

considered by Congress, which includes several important measures to

help advance the development of cellulosic ethanol, including:

-- Higher funding for research and development, demonstration

facilities, and specifically, additional funding for loan

guarantees (from the Department of
'/>"/>

SOURCE Verenium Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008).../ -- The Providence Service,Corporation (Nasdaq: ... Company,s,Chief Operating Officer, has been appo...orris, appointment fills the vacancy left by the A...eturns the board to six members. Mr.,Norris will... Mr. Norris, age 41, has been with Providence sinc...
(Date:11/21/2008)...que to combat cancer, study says, , ,...rchers have discovered that some cancer cells use ...ght lead to new treatments that starve and kill th...lls in the body need to produce energy. They do th...ires oxygen. Compared with normal cells, tumor cel...
(Date:11/21/2008)...ect Investment And Restore Shareholder Value , ...-- Dr. Stephen Joffe, Craig Joffe, and Alan Buckey...th the U.S. Securities and Exchange Commission. T...ip of 11.4% of LCA-Vision, Inc. (Nasdaq: LCAV ),...on correction centers in 33 states in the United S...
(Date:11/21/2008)...l/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL ) to... approved the proposals submitted to them relating...s Industries Ltd. (Nasdaq: TEVA ). , , "... of the transaction by the Barr shareholders," sai...e pleased with the progress that we continue to ma...
Breaking Medicine News(10 mins):Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:New Approach Keeps Tumor Cells From Refueling 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 2Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 3Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 4Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 5Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 6Health News:Founders & Former Executive Management Team of LCA-Vision Seek Change to Rescue Company 7Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4
... year received gifts for Christmas that may result...ly confine children to their houses and thereby ma...t Wales Institute of Higher Education (NEWI) revea...kids. X-mas gifts fail to encourage children to go...
...nne Murabito and team have reported that the risk ...ho have their siblings with heart disease.// Thoug...t disease is genetically susceptible and risk incr...dy has shown a 45% increased risk of heart disease...
...ng comes a study that states that about one-third ...o 49 years) in the U.S. have poor cardio respirato...holesterol and blood pressure levels. The study is...JAMA. There has been a strong correlation betwee...
...on children’s will be hi-tech whiz kids but would ...o indoor games with no physical activity.// A surv...er Education found that there is an increase in ob...nd poor diet rich in fatty foods due to fast food....
Other Medicine News:
(Date:11/20/2008)...swire-FirstCall/ -- Duska Therapeutics,Inc., (OT...as submitted its,pivotal Phase 3 ATPace clinical ...l Assessment (SPA) procedure with the U.S. Food an...securing an agreement with the FDA, Duska intends ...placebo-controlled and randomized Phase 3,clinica...
(Date:11/20/2008)...tCall/ -- PAREXEL International Corporation (Nasda...rvices provider, today announced that it has opene...nsulting and clinical research capabilities. With ...ocations throughout five important biopharmaceutic...gentina, Brazil, Chile, and Mexico. This expansion...
(Date:11/19/2008)...PRNewswire-FirstCall/ -- Amgen,(Nasdaq: AMGN ) ...sidiary of,Takeda Pharmaceutical Company Limited ...he Phase 3 MONET1 trial evaluating motesanib (AMG ...in for the first-line treatment of,advanced non-s... suspended,following a planned safety data review...
(Date:11/19/2008)...ewswire/ -- Biotech scientists increasingly are ap...h to better understand the effects of novel drug c...Genetic Engineering & Biotechnology News ( GE...t a new compound,s mechanism of action and eventua...according to the November 15 issue of GEN . ( htt...
Breaking Medicine Technology:Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7GEN Reports on the Trend Toward Predictive Toxicogenomics 2World Famous DavidBartonGym Buffs up the Bravern 12788 1World Famous DavidBartonGym Buffs up the Bravern 12788 2World Famous DavidBartonGym Buffs up the Bravern 12788 3Implementers Advocates Researchers Call on Congress to Honor Lantos Commitment to Public Health and Human Rights by Placing Evidence over Ideology 12785 1Implementers Advocates Researchers Call on Congress to Honor Lantos Commitment to Public Health and Human Rights by Placing Evidence over Ideology 12785 2Implementers Advocates Researchers Call on Congress to Honor Lantos Commitment to Public Health and Human Rights by Placing Evidence over Ideology 12785 3Implementers Advocates Researchers Call on Congress to Honor Lantos Commitment to Public Health and Human Rights by Placing Evidence over Ideology 12785 4Plexus Systems Inc Names Stosz to Solutions Engineer 12783 1Plexus Systems Inc Names Stosz to Solutions Engineer 12783 2Plexus Systems Inc Names Khanna to Senior Account Manager Western Region 12779 1Plexus Systems Inc Names Khanna to Senior Account Manager Western Region 12779 2
...INESS WIRE)--Apr 19, 2007 - Othera Pharmaceuticals...essor of,Pharmacology and Executive Vice President...tute at Albany College of Pharmacy,will present n...ombotic effect of Othera,s lead compound, OT-551, ... previous ocular,studies on OT-551 eye drops, as w...
..., April 19, 2007 /PRNewswire-FirstCall/ --,CuraGen...at,preliminary interim clinical data on intravenou...) inhibitor being investigated,for the treatment o...ming major medical meetings. , One oral and one po...lts with belinostat will be made at the 2007 Ameri...
Other Medicine Technology:Othera Pharmaceuticals Announces Upcoming Presentation Based Upon,Expanded Understanding of Lead Compound Mechanism of Action 2Othera Pharmaceuticals Announces Upcoming Presentation Based Upon,Expanded Understanding of Lead Compound Mechanism of Action 3Othera Pharmaceuticals Announces Upcoming Presentation Based Upon,Expanded Understanding of Lead Compound Mechanism of Action 4CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 2CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 3CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 4CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 5
Wet-Field Hemostatic Eraser bipolar tip, packsize is 5/box.
Sterile cordless eraser tips, packsize is 10/box.
Hydroview insertion forcep with very thin jaws to allow insertion through tunnel or clear cornea incision. Locking. Made in titanium.
Bi-angled insertion jaws designed to enhance surgeon comfort and efficiency. Reverse action releases lens when handle is compressed. Made in titanium.
Medicine Products: